SI1877070T1 - Terapevtska uporaba TGF-beta2 protismiselnih oligonukleotidov - Google Patents
Terapevtska uporaba TGF-beta2 protismiselnih oligonukleotidovInfo
- Publication number
- SI1877070T1 SI1877070T1 SI200630221T SI200630221T SI1877070T1 SI 1877070 T1 SI1877070 T1 SI 1877070T1 SI 200630221 T SI200630221 T SI 200630221T SI 200630221 T SI200630221 T SI 200630221T SI 1877070 T1 SI1877070 T1 SI 1877070T1
- Authority
- SI
- Slovenia
- Prior art keywords
- tgf
- antisense oligonucleotides
- therapeutic use
- oligonucleotide
- beta3
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 abstract 2
- 102000003814 Interleukin-10 Human genes 0.000 abstract 2
- 108090000174 Interleukin-10 Proteins 0.000 abstract 2
- 102100027584 Protein c-Fos Human genes 0.000 abstract 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 abstract 2
- 102100023132 Transcription factor Jun Human genes 0.000 abstract 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 abstract 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 abstract 2
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 abstract 2
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 2
- 229960002986 dinoprostone Drugs 0.000 abstract 2
- 229940076144 interleukin-10 Drugs 0.000 abstract 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 2
- 101150082674 E2 gene Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05009802 | 2005-05-05 | ||
| US68049305P | 2005-05-13 | 2005-05-13 | |
| EP06755024A EP1877070B1 (en) | 2005-05-05 | 2006-05-04 | Therapeutic use of tgf-beta2 antisense oligonucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1877070T1 true SI1877070T1 (sl) | 2009-06-30 |
Family
ID=36370983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200630221T SI1877070T1 (sl) | 2005-05-05 | 2006-05-04 | Terapevtska uporaba TGF-beta2 protismiselnih oligonukleotidov |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8097597B2 (sl) |
| EP (2) | EP1877070B1 (sl) |
| JP (2) | JP4977035B2 (sl) |
| AT (1) | ATE418992T1 (sl) |
| AU (2) | AU2006243218B2 (sl) |
| BR (1) | BRPI0611452A2 (sl) |
| CA (1) | CA2591586A1 (sl) |
| CY (1) | CY1108944T1 (sl) |
| DE (1) | DE602006004578D1 (sl) |
| DK (1) | DK1877070T3 (sl) |
| ES (1) | ES2319332T3 (sl) |
| MX (1) | MX2007007184A (sl) |
| NZ (1) | NZ562954A (sl) |
| PL (1) | PL1877070T3 (sl) |
| PT (1) | PT1877070E (sl) |
| RU (1) | RU2427377C2 (sl) |
| SI (1) | SI1877070T1 (sl) |
| WO (1) | WO2006117400A2 (sl) |
| ZA (2) | ZA200709237B (sl) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1877070T3 (da) | 2005-05-05 | 2009-03-02 | Antisense Pharma Gmbh | Terapeutisk anvendelse af TGF-beta2 antisense-oligonucleotider |
| EP1935428A1 (en) * | 2006-12-22 | 2008-06-25 | Antisense Pharma GmbH | Oligonucleotide-polymer conjugates |
| US8822425B2 (en) | 2008-11-14 | 2014-09-02 | Antisense Pharma Gmbh | Dosage of oligonucleotides suitable for the treatment of tumors |
| KR101410560B1 (ko) * | 2008-11-14 | 2014-07-01 | 안티센스 파마 게엠베하 | 종양의 치료에 적합한 올리고뉴클레오티드의 용량 |
| SG171914A1 (en) | 2008-12-02 | 2011-07-28 | Chiralgen Ltd | Method for the synthesis of phosphorus atom modified nucleic acids |
| AU2010270714B2 (en) | 2009-07-06 | 2015-08-13 | Wave Life Sciences Ltd. | Novel nucleic acid prodrugs and methods use thereof |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| EP2453017A1 (en) * | 2010-11-12 | 2012-05-16 | Antisense Pharma GmbH | Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases |
| DK2734208T3 (en) | 2011-07-19 | 2017-06-19 | Wave Life Sciences Ltd | PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS |
| JP6246121B2 (ja) | 2012-07-13 | 2017-12-13 | 株式会社新日本科学 | キラル核酸アジュバント |
| US9598458B2 (en) | 2012-07-13 | 2017-03-21 | Wave Life Sciences Japan, Inc. | Asymmetric auxiliary group |
| SG11201500232UA (en) | 2012-07-13 | 2015-04-29 | Wave Life Sciences Pte Ltd | Chiral control |
| CN105793422B (zh) * | 2013-09-05 | 2020-03-03 | 萨罗塔治疗公司(美国) | 酸性α-葡糖苷酶中反义诱导的外显子2纳入 |
| EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| US10160969B2 (en) | 2014-01-16 | 2018-12-25 | Wave Life Sciences Ltd. | Chiral design |
| US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
| DE102019000490A1 (de) * | 2019-01-23 | 2020-07-23 | HAEMES Verwaltungsgesellschaft mbH | Verwendung von Oligonukleotiden für die Behandlung von Tumoren |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| WO1989005358A1 (en) | 1987-11-30 | 1989-06-15 | University Of Iowa Research Foundation | Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5914396A (en) | 1990-01-11 | 1999-06-22 | Isis Pharmaceuticals, Inc. | 2'-O-modified nucleosides and phosphoramidites |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| TW244371B (sl) | 1992-07-23 | 1995-04-01 | Tri Clover Inc | |
| US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| WO1994025588A2 (en) * | 1993-04-30 | 1994-11-10 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β) |
| EP1160319A3 (en) | 1993-04-30 | 2002-03-06 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (TGF-beta) |
| ATE177430T1 (de) | 1993-05-12 | 1999-03-15 | Novartis Erfind Verwalt Gmbh | Nukleoside und oligonukleotide mit 2'- ethergruppen |
| DE69433520T2 (de) * | 1993-07-10 | 2004-11-11 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | Antisense-nukleinsäure enthaltende pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zelltod, und zur behandlung von neoplasmen |
| US5641756A (en) * | 1993-07-27 | 1997-06-24 | Hybridon, Inc. | Modified VEGF oligonucleotides |
| EP0695534B1 (en) | 1994-08-02 | 2001-11-07 | Olympus Optical Co., Ltd. | Endoscopic grasping device |
| US5591721A (en) | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| EP0856579A1 (en) | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | An antisense oligonucleotide preparation method |
| ES2226414T3 (es) | 1998-06-10 | 2005-03-16 | Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh | Estimulacion del sistema inmunitario. |
| EP1133988A1 (en) | 2000-03-11 | 2001-09-19 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| US7963956B2 (en) * | 2003-04-22 | 2011-06-21 | Antisense Pharma Gmbh | Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique |
| JP4871732B2 (ja) * | 2003-12-19 | 2012-02-08 | アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物 |
| AU2005218759B2 (en) * | 2004-02-27 | 2009-07-16 | Antisense Pharma Gmbh | Pharmaceutical composition |
| DK1877070T3 (da) | 2005-05-05 | 2009-03-02 | Antisense Pharma Gmbh | Terapeutisk anvendelse af TGF-beta2 antisense-oligonucleotider |
-
2006
- 2006-05-04 DK DK06755024T patent/DK1877070T3/da active
- 2006-05-04 RU RU2007145046/15A patent/RU2427377C2/ru not_active IP Right Cessation
- 2006-05-04 WO PCT/EP2006/062067 patent/WO2006117400A2/en active Application Filing
- 2006-05-04 ES ES06755024T patent/ES2319332T3/es active Active
- 2006-05-04 PT PT06755024T patent/PT1877070E/pt unknown
- 2006-05-04 DE DE602006004578T patent/DE602006004578D1/de active Active
- 2006-05-04 NZ NZ562954A patent/NZ562954A/en not_active IP Right Cessation
- 2006-05-04 JP JP2007551691A patent/JP4977035B2/ja not_active Expired - Fee Related
- 2006-05-04 PL PL06755024T patent/PL1877070T3/pl unknown
- 2006-05-04 EP EP06755024A patent/EP1877070B1/en active Active
- 2006-05-04 SI SI200630221T patent/SI1877070T1/sl unknown
- 2006-05-04 MX MX2007007184A patent/MX2007007184A/es active IP Right Grant
- 2006-05-04 US US11/792,041 patent/US8097597B2/en not_active Expired - Fee Related
- 2006-05-04 ZA ZA200709237A patent/ZA200709237B/xx unknown
- 2006-05-04 EP EP08173070.7A patent/EP2062586B1/en active Active
- 2006-05-04 CA CA002591586A patent/CA2591586A1/en not_active Abandoned
- 2006-05-04 AU AU2006243218A patent/AU2006243218B2/en not_active Ceased
- 2006-05-04 BR BRPI0611452-0A patent/BRPI0611452A2/pt not_active Application Discontinuation
- 2006-05-04 AT AT06755024T patent/ATE418992T1/de active
-
2008
- 2008-10-31 ZA ZA2008/09354A patent/ZA200809354B/en unknown
-
2009
- 2009-03-27 CY CY20091100366T patent/CY1108944T1/el unknown
- 2009-12-10 JP JP2009280553A patent/JP2010090159A/ja active Pending
- 2009-12-17 AU AU2009251023A patent/AU2009251023B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US8097597B2 (en) | 2012-01-17 |
| EP1877070A2 (en) | 2008-01-16 |
| CA2591586A1 (en) | 2006-11-09 |
| PL1877070T3 (pl) | 2009-06-30 |
| AU2009251023A1 (en) | 2010-01-14 |
| EP1877070B1 (en) | 2008-12-31 |
| PT1877070E (pt) | 2009-03-13 |
| WO2006117400A2 (en) | 2006-11-09 |
| BRPI0611452A2 (pt) | 2010-09-08 |
| RU2007145046A (ru) | 2009-06-10 |
| JP4977035B2 (ja) | 2012-07-18 |
| ZA200709237B (en) | 2009-04-29 |
| US20090306176A1 (en) | 2009-12-10 |
| CY1108944T1 (el) | 2014-07-02 |
| EP2062586B1 (en) | 2017-03-15 |
| AU2009251023B2 (en) | 2012-02-02 |
| MX2007007184A (es) | 2008-01-14 |
| RU2427377C2 (ru) | 2011-08-27 |
| DE602006004578D1 (de) | 2009-02-12 |
| EP2062586A3 (en) | 2009-08-12 |
| ATE418992T1 (de) | 2009-01-15 |
| ES2319332T3 (es) | 2009-05-06 |
| ZA200809354B (en) | 2010-02-24 |
| WO2006117400A3 (en) | 2007-01-25 |
| NZ562954A (en) | 2009-10-30 |
| EP2062586A2 (en) | 2009-05-27 |
| AU2006243218B2 (en) | 2009-09-17 |
| AU2006243218A1 (en) | 2006-11-09 |
| DK1877070T3 (da) | 2009-03-02 |
| JP2008528460A (ja) | 2008-07-31 |
| JP2010090159A (ja) | 2010-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1877070T1 (sl) | Terapevtska uporaba TGF-beta2 protismiselnih oligonukleotidov | |
| SG171676A1 (en) | Compositions and methods for inhibiting expression of the pcsk9 gene | |
| AR039717A1 (es) | Construcciones de arn de intrones cadena doble y usos de las mismas | |
| WO2007146511A3 (en) | Compounds and methods for modulating gene expression | |
| WO2006110688A3 (en) | Rnai therapeutic for respiratory virus infection | |
| SG170780A1 (en) | Compositions and methods for inhibiting expression of eg5 gene | |
| WO2007051045A3 (en) | Compositions and methods for inhibiting expression of huntingtin gene | |
| WO2008036933A3 (en) | Compositions and methods for inhibiting expression of the hamp gene | |
| WO2001048190A8 (en) | Therapeutic uses of lna-modified oligonucleotides | |
| ATE460481T1 (de) | Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung | |
| WO2009142822A3 (en) | 2-f modified rna interference agents | |
| WO2008116860A3 (en) | Dsrna compositions and methods for treating hpv infections | |
| WO2006032041A3 (en) | Compositions and methods for inhibiting expression of anti-apoptotic genes | |
| WO2007137156A8 (en) | Rnai modulation of aha and therapeutic uses thereof | |
| EP2031057A4 (en) | OLIGONUCLEOTIDE SENS CAPABLE OF REGULATING EXPRESSION OF INOS AND COMPOSITION CONTAINING SAME | |
| WO2007127919A3 (en) | Compositions and methods for inhibiting expression of a gene from the jc virus | |
| JP2007530431A5 (sl) | ||
| WO2007137220A3 (en) | Compositions and methods for inhibiting expression of ikk-b gene | |
| HK1159988A1 (en) | Compositions and methods for inhibiting expression of factor v leiden mutant gene | |
| JP2007517498A5 (sl) | ||
| AU2003253197A8 (en) | Targeted gene modification by single-stranded dna oligonucleotides | |
| WO2008041933A3 (en) | Rna interference against wrap53 to treat hyperproliferative diseases | |
| WO2007087544A3 (en) | Novel compositions of chemically modified small interfering rna |